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Orange GAbstract New sensitive and rapid spectrophotometric methods for the determination of four anal-
gesic drugs namely, nalbuphine (NALB), naltrexone (NALT), morphine (MORF) and tramadol
(TRAM) in pharmaceutical formulations were developed and optimized. The proposed methods
involve the addition of a measured excess of N-bromosuccinimide in acid medium followed by
determination of unreacted NBS by reacting with either a ﬁxed amount of methyl orange and mea-
suring the absorbance at 508 nm (Method A), or orange G and measuring the absorbance at 478 nm
(Method B). In both methods, the amount of NBS reacted corresponds to the amount of drugs.
Under the optimum conditions, Beer’s law limit, molar absorptivity and Sandell’s sensitivity were
calculated. The limits of detection and quantiﬁcation were also reported for both methods. Statis-
tical evaluation of the methods was examined by determining intra-day and inter-day precisions.
The methods were successfully applied to the assay of drugs in their pharmaceutical formulations.
No interference was observed from common additives and the validity of the methods was tested.
ª 2013 Production and hosting by Elsevier B.V. on behalf of University of Bahrain.1. Introduction
Nalbuphine ()-17-(cyclobutylmethyl)-4,5a-epoxymorphinan-
3,6a,14-triol (Fig. 1a) is a semisynthetic narcotic agonist–
antagonist of the phenanthrene series. Structurally, it is closely
related to naloxone, an antagonist of the opiate receptors and
to oxymorphone, a narcotic agonist. Nalbuphine has been
shown to be approximately equianalgesic to morphine, yetwith a ceiling effect on ventilator depression and fewer adverse
effects than pethidine or pentazocine. As an analgesic agent, it
is almost as potent as morphine and has been widely used in
the treatment of acute and chronic pain (Pick et al., 1992).
Its main advantages over morphine are a ceiling effect of respi-
ratory depression, low tolerance liability and a lack of signiﬁ-
cant withdrawal symptoms. It is available as an injection for
intramuscular and intravenous administration. The usual rec-
ommended doses are 10–20 mg by intravenous or intramuscu-
lar injection every 3–4 h. As to our best knowledge, there is no
ofﬁcial analytical method for analyzing NALB in ampoule, in
pharmacopoeias and the literatures.
a- Nalbuphine                                             b- Naltrexone
c- Tramadol d- Morphine
Figure 1 Chemical structure of the selected drugs.
44 A.M. El-Didamony et al.A few methods have been described to detect nalbuphine in
pharmaceutical formulations and in biological ﬂuids; they in-
clude gas chromatography coupled to electron-capture detec-
tion (Weinstein et al., 1978), or mass spectrometry (Yoo
et al., 1995), high-performance liquid chromatography with
electrochemical detection (Groenendaal et al., 2005; Pao
et al., 2000) and LC–MS/MS (Cai et al., 2011). The GC meth-
ods (Yoo et al., 1995), although sensitive, involved expensive
equipment and time consuming preparation of samples and
are not easily available for routine drug monitoring.
Naltrexone (17-cyclopropylmethylmethyl-6-deoxy – 7,8 –
dihydro-14-hydroxy-6-oxo-17-normorphine) (Fig. 1b), is a
long-acting synthetic opiate antagonist with few side effects
that is efﬁcacious when administered orally, either daily or
three times a week for a sustained period of time. Naltrexone
has been determined by using a wide variety of analytical tech-
niques, particularly chromatographic, such as high-perfor-
mance liquid chromatography (HPLC) with electrochemical
detection (Bru¨nen et al., 2010), liquid chromatography (Slaw-
son et al., 2007), and gas chromatography coupled with mass
spectrometry (Mehrdad et al., 2009).
Tramadol hydrochloride is a centrally acting analgesic,
used for treating moderate to severe pain. Tramadol hydro-
chloride possesses agonist actions at the l-opioid receptor
and effects reuptake at the noradrenergic and serotonergic sys-
tems. Tramadol is a compound with l-agonist activity. Chem-
ically it is [2-(dimethylaminomethyl)-1-(3-methoxyphenyl)
cyclohexanol)], (Fig. 1c). It is used to treat moderate to mod-
erately severe pain and most types of neuralgia, including tri-
geminal neuralgia. The BP (British Pharmacopoeia, 2003),
speciﬁes the non-aqueous titration technique detecting the
end point potentiometrically for the determination of tramadol
and dothiepin hydrochlorides while acebutolol was assayed inaqueous medium using 0.1 M NaOH titrant. Because of its
wide use, several techniques have been reported for its assay
in biological and pharmaceutical samples that include a num-
ber of high-performance liquid chromatographic (HPLC)
(Chandra et al., 2012; Saccomanni et al., 2010), electrochemi-
cal (Garrido et al., 2003), potentiometric methods (Ganjali
et al., 2008; Abu Shawish et al., 2011), and amperometry (Mal-
ongo et al., 2008), voltammetry (Ghorbani-Bidkorbeh et al.,
2010), and ﬂow injection chemiluminescence spectrophotome-
try (Zhang et al., 2009). The literature reported three spectro-
photometric methods differed from our described work (Anis
et al., 2011; Abdellatef et al., 2006).
Morphine (5a,6a-didehydro-4,5-epoxy-17-methylmorph-
inan-3,6-diol) (Fig. 1d), is a therapeutic drug that is used com-
monly for the control of pain and also abused as an illicit drug.
It is recommended by the World Health Organization (WHO)
for the relief of moderate cancer-related pain. Moreover, her-
oin is hydrolyzed in the organism to morphine; therefore, the
determination of morphine content of biological samples is
helpful for clinical and forensic purposes (Hoffman et al.,
1997). However, it is toxic in excess and when abused. To pre-
vent overdose-induced toxication, it is necessary to sensitively
monitor the concentrations of morphine in a patient’s blood or
urine. Various analytical methods have been developed for the
determination of morphine and its major metabolites. The
most common analytical techniques currently used include
gas chromatography (Matyus et al., 2012; Barroso et al.,
2010), high-performance liquid chromatography (Berga
et al., 2009; Ruzilawati et al., 2012), and their combination
with other detection methods, capillary electrophoresis (Mi
et al., 2004), chemiluminescence (Francisa et al., 2008), vol-
tammetric (Ali et al., 2011; Li et al., 2009), and electrochemical
(Li et al., 2010). To the best of our knowledge, only a report
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tometry (Sheibani et al., 2010).
Reviewing the literature revealed that, up to the present
time nothing has been published concerning the spectropho-
tometric determination of nalbuphine and naltrexone and lit-
tle detection has been reported for the determination of
morphine and tramadol by spectrophotometric methods.
For these reasons, the present study describes simple, sensi-
tive and economical spectrophotometric methods for the
analysis NALB, NALT, MORF and TRAM in pure and
pharmaceutical preparations. Analytical criteria including
linearity, sensitivity, precision, accuracy and recovery are
discussed.
2. Experimental
2.1. Apparatus
All the absorbance spectral measurements were made using
spectroscan 80 D double-beam UV/Vis spectrophotometer
(Biotech Engineering Ltd., UK), with wavelength range 190–
1100 nm, spectral bandwidth 2 nm, with 10 mm matched
quartz cells.
2.2. Reagents and materials
All reagents and chemicals used were of analytical or pharma-
ceutical grade and all solutions were prepared fresh daily.
2.2.1. Standard solution of pure drugs
A stock standard solution containing 20 mg of nalbuphine
(NALB), naltrexone (NALT), morphine (MORF) and trama-
dol (TRAM) was prepared by dissolving an appropriate
weight of pure drugs in distilled water and made up to the
mark in a 100 mL calibrated ﬂask. The analytical standard
solutions of drugs were prepared daily by appropriate dilution
of the stock standard solution in water.
2.2.2. N-bromosuccinimide (0.01%)
A stock solution of 0.01% N-bromosuccinimide (Aldrich Co.,
Ltd., Gillingham-Dorst, Germany) [1-Bromo-2,5-pyrrolidin-
edione], (C4H4BrNO2, M.Wt. 177.98 g mol
1) was freshly pre-
pared by dissolving 10 mg of NBS in a least amount of warm
water in a 100 mL measuring ﬂask and then diluted with dis-
tilled water to the mark.
2.2.3. Methyl orange (5 · 104 M)
A stock solution of 5 · 104 M methyl orange (E. Merck)
[4-dimethylaminoazobenzene-40-sulfonic acid sodium salt],
(C14H14N3NaO3S, M.Wt. 327.33 g mol
1) was prepared by
dissolving 16.36 mg of dye (99% purity) in distilled water
and diluting to 100 mL in a measuring ﬂask with distilled
water.
2.2.4. Orange G (1 · 103 M)
A stock solution of 1 · 103 M orange G (Aldrich) [1-Pheny-
lazo-2-naphthol-6,8-disulfonic acid disodium salt], (C16H10N2-
Na2O7S2, M.Wt. 452.38 g mol
1) was prepared by dissolving
45.2 mg of dye in distilled water and diluting to 100 mL in a
measuring ﬂask with distilled water.2.2.5. Hydrochloric acid (0.5 M)
A 0.5 M of HCl was prepared by diluting 4.47 mL of concen-
trated acid (Merck, Darmstadt, Germany, sp. gr. 1.18%, 37%)
to 100 mL with distilled water.
2.2.6. Potassium bromide (1.0%)
A 1% KBr solution is used.
2.3. Recommended procedures
2.3.1. Method A: using methyl orange dye
Aliquot solutions of pure NALB (1.0–4.5 lg mL1), NALT
(1.5–6.5 lg mL1), MORF (1.0–4.0 lg mL1) and TRAM
(1.0–5 lg mL1) were transferred into a series of 10 mL volu-
metric ﬂasks by means of a micro buret. Then, 0.6 mL of 0.5 M
HCl was added; followed by 1.0 mL of 0.01% NBS for TRAM
and MORF; 0.8 and 1.2 mL for NALT and NALB, respec-
tively and then add 0.5 mL of 1.0% KBr. The contents were
mixed and then left for 5 min at room temperature, with occa-
sional shaking. Finally, add 0.8, 0.7, 0.6 and 1.1 mL of
5 · 104 M MO for TRAM, MORF, NALT and NALB,
respectively. The absorbance of the solution was measured at
508 nm against a blank solution prepared by the same way
without drugs.
2.3.2. Method B: using orange G dye
Varying aliquots of standard solution of NALB (1.0–6.0 lg
mL1), NALT (0.5–7.0 lg mL1), MORF (1.0–6.0 lg mL1)
and TRAM (1.0–7.0 lg mL1) were transferred into a series
of 10 mL volumetric ﬂasks by means of a micro buret. Then,
0.6 mL of 0.5 M HCl was added; followed by 1.0 mL of
0.01% NBS for TRAM, NALT and NALB, and 1.4 mL for
MORF and then add 0.5 mL of 1.0% KBr. The contents were
mixed and then left for 5 min at room temperature. Finally,
add 1.2 mL of 1 · 103 M of OG for each drug and the solu-
tion was allowed to stand at room temperature for 5 min.
Complete to 10 mL with distilled water. The absorbance of
the solution was measured at 478 nm against a blank solution
prepared by the same way without drugs. In either method, the
concentration of the unknown was read from the calibration
graph or calculated using the regression equation obtained
by using Beer’s law.
2.3.3. Procedure for the tablets
Ten tablets of deltrexone (Manufactured by Delta Pharmaceu-
ticals Co., Egypt) each containing 50 mg of NALT were
crushed, powdered, weighed out and the average weight of
one tablet was determined. An accurate weight equivalent to
20 mg of NALTwas dissolved in 20 mL distilled water and then
ﬁltered. The ﬁltrate was diluted to 100 mL with distilled water
in a 100 mL measuring ﬂask. This solution was further diluted
stepwise to the required concentration with water and then ana-
lyzed as described under the general procedure. Suitable dilu-
tion was made to ﬁt the applicable concentration range and
the above described procedures were followed. The nominal
content of the tablet was assayed from the calibration curves.
2.3.4. Procedure for ampoules
The content of ﬁve naluﬁn ampoules (20 mg mL1) of nal-
buphine, ﬁve morphine ampoules labeled to contain 20 mg
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factured by Misr Pharmaceuticals Co., Egypt) were mixed
and the average volume of one ampoule was determined.
Accurately measured volume equivalent to 20 mg of each
drug was transferred into a 100 mL measuring ﬂask and di-
luted to the mark with distilled water. Suitable dilution was
made to ﬁt the applicable concentration range and the above
described procedures were followed. The nominal content of
the ampoules was calculated either from calibration graph or
using the regression equation.
3. Results and discussion
3.1. Optimum conditions
The effects of the reagent concentrations, temperature, mix-
ing time, order of addition with respect to maximum sensi-
tivity, minimum blank adherence to Beer’s law and stability
were studied through control experiments. The optimum
conditions were established by varying one variable and
observing its effect on the absorbance of the colored
products.
3.1.1. Absorption spectra
The proposed methods are based on the oxidation of
TRAM, MORF, NALT and NALB drugs by adding a
known excess of NBS in HCl medium, then left for ﬁxed
time to enhance the oxidation process of the drugs. After
the oxidation of the drugs was ensured to be complete; then
the unreacted NBS was reacted with a ﬁxed quantity of dye
(MO and OG) and the resulting change in absorbance was
measured at 508 nm for MO and for OG at 478 nm. The de-
crease in concentration of NBS upon reacting with a ﬁxed
concentration of MO and OG resulted in an increase in
absorbance at 508 nm and 478 nm respectively, due to the
bleaching of dyes by the oxidant, which is related to the
drug concentrations and the discoloration being caused by
the oxidative destruction of the dyes (Fig. 2). This is ob-
served as a proportional increase in the absorbance of MO
and OG with an increase in the concentrations of TRAM,
MORF, NALT and NALB, which formed the basis for
the assay.
3.1.2. Chemistry of the reactions
NBS is widely used as an oxidizing or brominating reagent
for the determination of many pharmaceutically important
compounds (Zenita and Basavaiah, 2011; Vinay et al.,
2011). It is also a speciﬁc reagent for the bromination of or-
ganic compounds at allylic position (Morison and Boyd,
1992). The analytical reactions involved two steps; the ﬁrst
one was concerned with the treatment of the investigated
drugs with a known excess amount of NBS. The second step
involved the determination of the excess unreacted NBS via
its reaction with a ﬁxed amount of both MO and OG dyes
and measuring the absorbance at either 508 nm or 478 nm,
respectively. In either method, the absorbance increased lin-
early with increasing concentration of drugs. The latter
methods make use of the bleaching action of NBS on either
dye, the discoloration being caused by the oxidative destruc-
tion of the dye.3.1.3. Effect of temperature and mixing time
The effect of temperature was studied by heating a series of
sample and blank solutions at different temperatures ranging
from 40 to 70 C in water bath. It was found that raising the
temperature does not accelerate the oxidation process and does
not give reproducible results, so maximum color intensity was
obtained at room temperature. The effect of mixing time re-
quired completing oxidation of the studied drugs and for
reducing the excess oxidant was studied by measuring the
absorbance of sample solution against blank solution prepared
similarly at various time intervals 5–30 min, at 508 and 478 nm
for methods A and B, respectively. It was found that the con-
tact times gave constant and reproducible absorbance values at
5 min at room temperature (25 ± 2 C) for each drug. The
time required for complete oxidation of the drug is not critical
and any delay up to 20 min in the determination of unreacted
NBS had no effect on the absorbance. A 5.0 min standing time
was found necessary for the complete bleaching of the dye col-
or by the residual NBS for each drug was found necessary for
complete reduction of residual NBS by the two dyes.3.1.4. Selection of acid type and acid concentration
The reactions were tested in HCl, H2SO4, HNO3, and CH3-
COOH solutions. The results indicate that the reaction is suit-
able in hydrochloric acid medium. A 0.5 M HCl was found to
be adequate for the oxidation of the drugs. The variation in
HCl concentration indicated that constant absorbance was ob-
tained with 0.2–2.0 mL of 0.5 M HCl for each drug; so subse-
quent studies were performed with 0.6 mL of 0.5 M HCl for
each drug.
3.1.5. Effect of NBS concentration
The effect of NBS concentration was examined in the range of
0.2–1.4 mL. It was found that maximum color intensity of the
products in case of MO was achieved with 1.0 mL of 0.01%
NBS for TRAM and MORF, but with 0.8 and 1.2 mL for
NALT and NALB, respectively while in case of OG, the max-
imum color intensity of the products was achieved with 1.0 mL
of 0.01% NBS for TRAM, NALT and NALB, but with
1.4 mL for MORF. The color intensity decreased above the
upper limit.
3.1.6. Sequence of addition
The best sequence of addition was drug-HCl-NBS-KBr and
then the dye. Other sequences gave lower absorbance value un-
der the same experimental conditions.
3.1.7. Effect of KBr concentration
The effect of KBr concentration was studied in the range of
0.5–2.5 mL. 0.5 mL of 1.0% KBr was chosen as the optimal
volume to accelerate the oxidation process.
3.1.8. Effect of dye concentration
The effect of MO and OG concentration on the intensity of
the color developed was carried out to obtain the optimum
concentration of dyes that produces the maximum and
reproducible color intensity by reducing the residual of
NBS. The effect of concentration of 5 · 104 M of MO
was studied in the range of 0.2–1.1 mL. It was found that
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Figure 2 Absorption spectra for I-MO and II-OG. (MO: (a) 1.0 lg mL1, (b) 2.5 lg mL1, (c) 4.0 lg mL1 and II-OG: (a) 1.0 lg mL1,
(b) 3.0 lg mL1, (c) 5.5 lg mL1 of MORF.
Table 1 Optical characteristics, statistical data of the regression equations and validation parameters for the studied drugs (n= 5).
Parameters MO OG
TRAM MORF NALT NALB TRAM MORF NALT NALB
kmax (nm) 508 508 508 508 478 478 478 478
Beer’s law limit, lg mL1 1–5 1–4 1.5–7 1–4.5 1–7 1–6 0.5–6 1–6
Molar absorptivity, L mol1 cm1 7.10 · 104 2.46 · 105 7.26 · 104 1.06 · 105 5.13 · 104 1.56 · 105 7.79 · 104 8.52 · 104
Sandell’s sensitivity, ng cm2 4.219 3.079 5.204 3.703 5.838 4.858 4.850 4.618
Correlation coeﬃcient (r) 0.9995 0.9995 0.9997 0.9995 0.9996 0.9998 0.9996 0.9997
Sy/x 0.0114 0.0127 0.0096 0.0107 0.0055 0.0068 0.0065 0.0060
Intercept (a) 0.1467 0.0646 0.3111 0.0393 0.5318 0.3458 0.5666 0.5749
Slope (b) 0.2675 0.3450 0.2423 0.2772 0.0960 0.1483 0.1117 0.1194
S.D. of slope (Sb) 0.0029 0.0048 0.0021 0.0035 0.0011 0.0016 0.0013 0.0014
S.D. of intercept (Sa) 0.0267 0.0318 0.0266 0.0278 0.0120 0.0139 0.0106 0.0123
LOD, lg mL1 0.1557 0.1355 0.1232 0.2168 0.1425 0.1947 0.1161 0.1371
LOQ, lg mL1 0.5184 0.4512 0.4102 0.7219 0.4745 0.6483 0.3866 0.4565
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achieved with 0.8 and 1.1 mL of 5 · 104 M MO for TRAM
and NALB, respectively, but with 0.7 mL for MORF and
NALT. The effect of concentration of 1 · 103 M of OGwas studied in the range of 0.4–1.4 mL and it was found
that the optimum concentration to have maximum absor-
bance was obtained with 1.2 mL of 1 · 103 M OG for each
drug.
Table 2 Evaluation of intra-day and inter-day accuracy and precision of the proposed methods using MO dye.
Drugs Taken lg mL1 Intra-day accuracy and precision Inter-day accuracy and precision
Founda lg mL1 Recovery, % RSD, % REb, % Founda lg mL1 Recovery, % RSD, % REb, %
TRAM 2.0 1.999 99.994 0.364 0.050 1.999 99.997 1.176 0.050
3.5 3.499 99.997 0.575 0.028 3.499 99.997 0.179 0.028
4.0 3.995 99.875 0.478 0.125 3.991 99.775 0.925 0.225
MORF 1.5 1.498 99.997 0.997 0.133 1.499 99.998 1.572 0.066
2.5 2.499 99.993 1.017 0.040 2.499 99.996 0.858 0.040
3.0 2.993 99.766 0.754 0.233 3.011 100.366 0.578 0.366
NALT 3.0 2.999 99.996 1.428 0.033 2.997 99.994 1.162 0.100
5.0 4.997 99.995 1.157 0.06 4.999 99.996 0.921 0.020
6.5 6.499 99.997 1.327 0.015 6.505 99.995 1.328 0.076
NALB 2.0 1.999 99.998 1.696 0.050 1.996 99.998 1.478 0.200
3.0 2.999 99.997 1.252 0.033 2.998 99.995 0.997 0.066
4.0 3.975 99.375 0.849 0.625 3.987 99.675 0.745 0.325
a Mean value of ﬁve determinations.
b RE: Relative error.
Table 3 Evaluation of intra-day and inter-day accuracy and precision of the proposed methods using OG dye.
Drugs Taken,
lg mL1
Intra-day accuracy and precision Inter-day accuracy and precision
Founda, lg mL1 Recovery, % RSD, % REb, % Founda, lg mL1 Recovery, % RSD, % REb, %
TRAM 2.5 2.499 99.998 1.251 0.040 2.495 99.995 1.047 0.200
3.5 3.487 99.996 1.181 0.371 3.516 99.995 0.450 0.457
5.0 5.011 99.994 0.595 0.220 4.999 99.997 0.470 0.020
MORF 1.5 1.496 99.998 1.610 0.266 1.495 99.994 1.451 0.333
2.5 2.507 99.995 0.898 0.280 2.499 99.996 1.178 0.040
4.0 3.999 99.994 1.100 0.025 3.997 99.998 1.241 0.075
NALT 3.0 3.015 99.998 0.825 0.500 2.989 99.997 0.938 0.366
4.0 3.995 99.875 0.974 0.125 3.989 99.725 1.145 0.275
5.0 4.988 99.996 1.186 0.240 4.991 99.996 1.008 0.180
NALB 2.0 1.999 99.996 0.843 0.050 2.008 99.995 0.728 0.400
3.0 2.996 99.997 1.010 0.133 2.991 99.996 1.559 0.300
4.5 4.494 99.995 1.018 0.133 4.488 99.994 0.810 0.266
a Mean value of ﬁve determinations.
b RE: Relative error.
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3.2.1. Analytical data
A linear correlation was found between absorbance at kmax
and concentration of the studied drugs. The graphs showed
negligible intercept and are described by the equation:
Y ¼ aþ bX
(where Y= absorbance of 1-cm layer of solution; a= inter-
cept; b= slope and X= concentration in lg mL1). Regres-
sion analysis of Beer’s law data using the method of least
squares was made to evaluate the slope (b), intercept (a) and
correlation coefﬁcient (r) for each system and the values are
presented in Table 1. The optical characteristics such as Beer’s
law limits, molar absorptivity and Sandell’s sensitivity values
of both methods are also given in Table 1. The limits of detec-tion (LOD) and quantitation (LOQ) calculated according to
ICH guidelines (Validation of Analytical Procedures, 1994)
are also presented in Table 1 and reveal the very high sensitiv-
ity of the methods.
3.2.2. Accuracy and precision
The precision of the proposed methods was calculated in
terms of intermediate precision (intra-day and inter-day).
Three different concentrations of the studied drugs were
analyzed in ﬁve replicates during the same day (intra-day
precision) and for seven consecutive days (inter-day preci-
sion). The analytical results obtained from the investigation
are summarized in Tables 2 and 3. The percentage relative
error (RE%) and the percentage relative standard deviation
(RSD%) are considered very satisfactory. This level of pre-
cision of the proposed methods was adequate for the quality
control analysis of the studied drugs.
Table 4 Assay results of NALB, NALT, MORF and TRAM in pharmaceutical preparations using MO and OG.
Drugs Name of
preparation
MO OG
Taken,
lg mL1
Founda,
lg mL1
Recovery,
%
RSD,
%
REb,
%
Taken,
lg mL1
Founda,
lg mL1
Recovery,
%
RSD,
%
REb,
%
NALB Naluﬁn 20 mg mL1 2.0 1.983 99.027 1.665 0.850 2.0 1.943 104.381 3.939 2.850
3.0 2.974 99.158 2.037 0.866 3.0 3.122 104.074 3.567 4.066
4.0 3.974 99.350 2.624 0.650 4.0 4.086 102.150 3.842 2.150
NALT Deltrexone 50 mg/tablet 3.0 3.096 103.205 4.841 3.200 3.0 2.857 100.031 0.787 4.766
5.0 5.164 103.297 3.704 3.280 5.0 5.207 96.199 3.257 4.140
6.5 6.590 100.015 1.459 1.384 6.5 6.411 97.28 3.109 1.369
MORF Morphine injection 20 mg mL1 1.5 1.483 98.875 2.660 1.133 1.5 1.547 96.623 3.552 3.133
2.5 2.436 97.464 3.132 2.800 2.5 2.538 97.616 3.465 1.520
3.5 3.471 99.171 1.312 0.828 4.5 4.448 98.844 0.835 1.155
TRAM Ampoules, 100 mg 2 mL1 2.0 2.041 102.087 3.404 2.050 2.0 2.052 103.258 3.736 2.600
3.5 3.621 103.477 3.490 3.457 3.5 3.473 104.335 3.893 0.771
4.5 4.416 98.133 2.951 1.866 5.0 5.151 103.352 3.797 3.020
a Mean value of ﬁve determinations.
b RE: Relative error.
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Robustness was examined by evaluating the inﬂuence of a
small variation of the method variables including the concen-
tration of analytical reagents and reaction time on the perfor-
mance of the proposed methods. In these experiments, one
parameter was changed whereas the others were kept un-
changed and the recovery percentage was calculated for each
time. It was found that small variations in these variables
did not affect the method signiﬁcantly. This was an indication
of the reliability of the proposed method during its routine
application for the analysis of the investigated drug and so
the proposed spectrophotometric methods are considered
robust.
3.3. Analysis of pharmaceutical formulations
The proposed methods have been successfully applied to deter-
mine TRAM, MORF, NALT and NALB in tablet and am-
poule dosage forms and the results obtained are satisfactorily
accurate and precise as indicated by the excellent% recovery
(Table 4).
4. Conclusion
The proposed methods have the advantages of simplicity
and rapidity for the determination of four analgesic drugs
in pure, pharmaceutical preparations. The assay methods in-
volve less stringent control of experimental parameters such
as the stability of the colored species, time of analysis and
temperature independence. The reagents utilized in the pro-
posed methods are cheaper, readily available and the proce-
dures do not involve any tedious sample preparation. These
advantages encourage the application of the proposed meth-
ods in routine quality control analysis of the selected drugs
in pharmaceutical formulations.References
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